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Rabbits were immunized with a novel regimen designed to focus the immune response on a single neutralizing epitope of HIV-1 gp120 and
thereby preferentially induce neutralizing antibodies (Abs). Animals were primed with gp120 DNA from a clade A Env bearing the GPGR V3
motif and/or a clade C Env bearing the GPGQ V3 motif, and boosted with one or more fusion proteins containing V3 sequences from clades A, B
and/or C. Immune sera neutralized three of four Tier 1 primary isolates, including strains heterologous to the immunizing strains, and potent cross-
clade-neutralizing activity was demonstrated against V3 chimeric pseudoviruses carrying in a Tier 1 Env, the consensus V3 sequences from clades
A1, AG, B, AE, or F. The broadest and most potent neutralizing responses were elicited with the clade C gp120 DNA and a combination of V3-
fusion proteins from clades A, B and C. Neutralizing activity was primarily due to V3-specific Abs. The results demonstrate that the immune
response can be focused on a neutralizing epitope and show that the anti-V3 Abs induced recognize a diverse set of V3 loops.
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Protective antibodies (Abs) are needed to reduce the size of a
virus inoculum and block infection of target cells. The ability of
Abs to afford such protection against HIV-1 (HIV) is documented
by several passive immunization experiments in animals (Baba
et al., 2000; Emini et al., 1990; Gauduin et al., 1997; Mascola
et al., 1999; Shibata et al., 1999) and by recent data suggesting
that neutralizing Abs in HIV-infected individuals protect against
superinfection (Smith et al., 2006).
Since sera from some HIV-infected individuals have broad
neutralizing activity (Nyambi et al., 1996; Pilgrim et al., 1997)
and several human mAbs neutralize a broad spectrum of pri-
mary isolates (Binley et al., 2004), it is clear that the human B
cell repertoire includes genes capable of coding for Abs that can⁎ Corresponding author. c/o VA Medical Center – Room 18124N, 423 East
23rd Street, New York, NY 10010, USA. Fax: +1 212 951 6321.
E-mail address: zollas01@med.nyu.edu (S. Zolla-Pazner).
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doi:10.1016/j.virol.2007.09.024recognize and neutralize a broad spectrum of HIV isolates. The
epitopes that are known to induce broadly neutralizing Abs
include the membrane proximal external region of gp41, the
CD4 binding site on gp120, complex glycans on gp120, the
CD4-induced epitope in and around the gp120 bridging sheet,
and the V3 loop of gp120 (Zolla-Pazner, 2004).
Despite the extensive information on HIV-neutralizing Abs,
it has proven difficult to induce broadly neutralizing Ab re-
sponses against HIV by immunization. This is due to several
factors including the predominant induction of non-neutralizing
rather than neutralizing Abs (Belshe et al., 1993; Gilbert et al.,
2005; Parren et al., 1997), the masking of neutralization-sensi-
tive epitopes (Fox et al., 1997; Krachmarov et al., 2006; Kwong
et al., 2002; Pinter et al., 2004; Wei et al., 2003), the high
mutation rate of HIV leading to antigenic variability, and a
myriad of other factors such as the physicochemical character-
istics of the virus membrane (Harada et al., 2005) and the
variable affinities of the different gp120 proteins for the virus
receptors (Hammond et al., 2001; Reeves et al., 2002).
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used as immunogens (including gp120, gp140, gp145, and
gp160, various oligomeric constructs, and several complete and
truncated forms of Env expressed as components of recombi-
nant viruses), the best, albeit modest, results in terms of gene-
rating cross-clade-neutralizing Abs have been achieved with
strategies utilizing a DNA prime and either a recombinant
adenovirus or protein boost. The promise of this approach was
first demonstrated with constructs derived from T cell line-
adapted HIV strains (Lu et al., 1998; Richmond et al., 1998),
and has more recently been confirmed and extended using HIV
env genes derived from various HIV strains including primary
isolates (Barnett et al., 2001; Barnett et al., 1997; Beddows
et al., 2005; Richmond et al., 1998; Wang et al., 2005a, 2006).
Thus, in rabbits, priming with gp120JR-FL DNA and boosting
with EnvJR-FL induced neutralizing Abs to the relatively re-
sistant homologous strain as well as to a limited number of other
clade B primary isolates but to no viruses from heterologous
clades (Wang et al., 2005a). Priming with a polyvalent cocktail
of gp120 DNA plasmids and boosting with a cocktail of Env
proteins from various clades induced a broader response, with
cross-clade neutralizing Abs to strains from clades A, B, C, D,
and E (Lian et al., 2005; Wang et al., 2006). Similarly, in guinea
pigs, a polyvalent env DNA prime and polyvalent boost with
recombinant adenoviruses, each carrying env genes from clades
A, B and C, resulted in Abs able to neutralize strains from these
clades, albeit at titers of only 1:5 (Chakrabarti et al., 2005).
In each of these experiments, the boosting immunogen was a
form of gp120 or gp145 which contains a multitude of B cell
epitopes.
An alternative immunization approach is the construction
and use of an immunogen that will focus the immune response
on one or a few epitopes that are known to induce neutralizing
Abs. An advantage of this approach is the potential to induce an
immune response with a larger proportion, and consequently a
higher titer of, neutralizing Abs. The use of selected epitopes or
mimotopes for the construction of vaccines that preferentially
induce protective Abs is still in its infancy, although some
striking examples exist, especially with polysaccharide antigens
of various pathogens (Beenhouwer et al., 2002; Buchwald et al.,
2005). In the search for an HIV vaccine, several attempts have
been made to graft a neutralizing epitope from the virus en-
velope into a foreign protein. For example, the neutralizing
epitope in the membrane proximal external region of gp41
recognized by human mAb 2F5 has been grafted into influenza
and the hepatitis B surface antigen (Eckhart et al., 1996; Muster
et al., 1995), however these constructs failed to induce neu-
tralizing Abs. In contrast, a peptide mimotope selected based on
binding to the broadly neutralizing human anti-V3 monoclonal
Ab 447, when covalently conjugated to a protein carrier,
induced an Ab response which, although limited in potency and
breadth, could neutralize two virus strains (Keller et al., 1993).
Another strategy, using a recombinant protein prime and
boosters containing V2 and V3 peptides resulted in increased
titers of anti-peptide Abs and an increase in serum neutralizing
Abs for the homologous and a related virus (Davis et al., 1997).
To further test the concept of “immunofocusing vaccines” inorder to enhance the quality and/or quantity of neutralizing Abs
in immune sera, we developed an immunization regimen de-
signed to focus the immune response on the V3 loop of gp120.
To do this, we used both classical immunologic approaches to
priming and selectively stimulating memory B cells (Ovary and
Benacerraf, 1963) and more recent data that stress the impor-
tance of the conformation of B cell epitopes (Gorny et al., 2002).
The V3 loop was chosen because many studies have shown
that anti-V3 Abs can neutralize diverse strains of HIV. Thus, it
has long been known that human mAbs directed against V3 can
neutralize primary isolates (Binley et al., 2004; Conley et al.,
1994; Gorny et al., 2004, 1997; Hioe et al., 1997) and that
polyclonal anti-V3 Abs in the sera of patients (Krachmarov
et al., 2005, 2001) and immunized guinea pigs and monkeys
(Chakrabarti et al., 2005; Liao et al., 2000; Yang et al., 2004)
have neutralizing activity. In addition, V3 is a highly immu-
nogenic region of the virus envelope (Carrow et al., 1991; Vogel
et al., 1994). It is formed by a continuous (rather than discon-
tinuous) stretch of amino acids, and anti-V3 Abs do not display
auto-reactive activity (Haynes et al., 2005). These features make
V3 a logical first target in efforts to induce a focused neu-
tralizing Ab response. In contrast, other neutralizing epitopes of
gp120 and gp41 are poorly immunogenic and/or are formed by
discontinuous regions in the envelope proteins (Gorny and
Zolla-Pazner, 2004; Zolla-Pazner, 2004). Though only about
20% of primary isolates are sensitive to anti-V3 Abs (Binley
et al., 2004; Li et al., 2005), a V3-focused vaccine would con-
stitute an important first step in the development of a vaccine
platform that must ultimately target additional neutralizing epi-
topes of the HIV envelope glycoproteins.
Here, we report the results of experiments in rabbits in which
new permutations to the prime/boost approach were used in
order to preferentially induce anti-V3 Abs. Thus, we primed, as
before, with one or more gp120 DNA constructs, all of which
contained multiple B and T cell epitope. Subsequently, we used
a protein boost which selectively stimulated only the HIV-
specific memory B cells directed against V3 epitopes, replacing
the more conventional boosting immunogens that contain all or
most Env epitopes.
The results provide a proof-of-principle that it is possible, in
this way, to focus the immune response on a neutralizing epi-
tope, and they show specifically the ability to induce a vigorous
anti-HIV Ab response focused on the V3 loop. This response
includes the production of neutralizing Abs which can recog-
nize and neutralize viruses and pseudoviruses carrying diverse
V3 loops.
Results
Design of immunogens and immunization protocols
Two sets of rabbits were immunized. As summarized in
Table 1 and detailed in Methods, the three rabbits in each group
received three priming doses of codon-optimized gp120 DNA
derived from env genes from primary isolates from clades A
and/or C, and two booster doses of gp120 or one or more V3-
fusion proteins (V3-FPs). The rabbits were bled before the
Table 1
Immunization groups for rabbit study
Group Immunizing regimen DNA primea at weeks 0, 2, and 4 Protein boosta at weeks 10 and 14
I-1 −/B – V3B-FP
I-2 AR/B gp120/Clade A (GPGR) V3B-FP
I-3 AR/gp120R gp120/Clade A (GPGR) gp120JR-FL
II-1 −/ABC – V3A-, V3B- and V3C-FP
II-2 AR/ABC gp120/Clade A (GPGR) V3A-, V3B- and V3C-FP
II-3 CQ/ABC gp120/Clade C (GPGQ) V3A-, V3B- and V3C-FP
II-4 AR+CQ/ABC gp120/Clade A (GPGR) and gp120/Clade C (GPGQ) V3A-, V3B- and V3C-FP
II-5 AR/B gp120/Clade A (GPGR) V3B-FP
aV3 sequences contained in priming and boosting constructs. Variations in sequence from relevant consensus sequences are underlined, and the variation at the tip of
the loop, position 18 (R/Q), is bolded.
CA1 clade A1 env gp120 DNA prime (AR): CTRPNNNTRKGIHIGPGRAIYATGDIIGDIRQAHC
92BR025.9 clade C env gp120 DNA prime (CQ): CTRPNNNTRKSIRIGPGQAFYATGEIIGDIRQAHC
V3A-FP derived from clade A strain 92UG037.08: CTRPNNNTRKSVRIGPGQTFYATGDIIGDIRQAHC
V3B-FP derived from clade B strain JR-CSF: CTRPSNNTRKSIHIGPGRAFYTTGEIIGDIRQAHC
V3C-FP derived from clade C strain 93IN904: CTRPNNNTRKSIRIGPGQTFYATGDIIGDIRQAHC
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each immunizing injection. The gp120 gene from CA1 (an R5-
tropic strain of CRF011_cpx) and from 92BR025.9 (an R5-tropic
strain of clade C) were chosen for preparation of the DNA prime.
The CA1 strain carries a gp120 of clade A andwas selected based
on previous experiments showing that its envelope was immuno-
logically representative of a cluster of unrelated primary isolates
from clades A, B, D, F and G (Nyambi et al., 2000). It is
noteworthy that the CA1 V3 sequence contains the GPGR V3
motif (Table 1) which is present in only ∼4% of clade A
envelopes (http://www.hiv.lanl.gov). The 92BR025.9 strain was
chosen as a representative clade C virus with the GPGQ motif at
the tip of the V3 loop (Table 1).
For the protein boosts, gp120 from the clade B JR-FL R5-
tropic strain was used because it carries the V3 consensus
sequence of clade B (with the GPGRV3motif). The V3JR-CSF-FP
(V3B-FP) was used as the boost because it had previously been
shown to present the V3 epitope in its immunologically correct
conformation (Kayman et al., 1994), and because the V3 of the
clade B JR-CSF strain differs from the clade B consensus
sequence by only one amino acid (Table 1). The V3A-FP differs
from the consensus sequence of clade A at two positions, and
the V3C-FPs carries the consensus V3 sequence of clade C (see
Table 1).
Immunization with GPGR-based vaccines: antibody levels
measured by ELISA
In the first experiment, both the prime and boost constructs
carried the GPGR V3 motif. To compare the effect of priming
and the boosting efficiency of gp120 vs. V3B-FP, three groups
of rabbits were used: Group I-1 (−/B),which received no prime
but was immunized with V3B-FP; Group I-2 (AR/B), which
received a clade A DNA gp120 prime which carries the GPGR
V3 motif (AR) followed by boosting with V3B-FP; and Group I-
3: (AR /gp120R), which received a clade A DNA gp120 prime
followed by boosting with gp120 protein from the JR-FL clade
B strain (see Table 1). To determine the specificity of the Absinduced by the various immunization regimens, the reactivities
of the sera from the various immunized animals were measured
against MuLV gp70 (the protein into which the V3 sequences
had been spliced to form the V3-FPs), against the YU2 gp120
core, and against the YU2 gp120 core carrying the V3 sequence
(gp120 core+V3) (Wu et al., 1996b). Sera tested were derived
from bloods drawn prior to immunization (pre-bleeds) and from
those obtained 2 weeks after the second protein boost. The sera
of animals that received V3-FP (Group I-1: −/B and Group I-2:
AR/B) made vigorous anti-gp70 responses, whereas, as antici-
pated, the sera of rabbits receiving no gp70 (Group I-3: AR /
gp120R), and the pre-bleed sera from all three groups, contained
no detectable anti-gp70 Abs (Fig. 1, left column).
To determine the levels of anti-V3 responses, serum reactivity
was tested against gp120 core and gp120 core+V3 (Fig. 1, right
column). As expected, sera drawn 2weeks after the second boost
from rabbits of Group I-1: −/B, which received only V3-FP,
reacted only with gp120 core+V3 and displayed essentially
no binding activity against gp120 core. Sera from rabbits of
Group I-2: AR/B displayed responses against gp120 core+V3
that were significantly greater than those against gp120 core
(half-maximal binding titers of 1:69,398 and 1:2,909, respec-
tively). This pattern of reactivity suggests that V3-FPwas able to
focus the Ab response on the V3 epitope. In contrast, the sera of
rabbits primed with gp120 DNA and boosted with gp120 protein
(Group I-3: AR /gp120R) displayed similar Ab reactivities
against gp120 core+V3 and gp120 core (half-max. titers of
1:217,126 and 1:147,365, respectively), demonstrating that
when gp120 protein is used as an immunogen, the V3 region is
not an immunodominant epitope.
Immunization with GPGR-based vaccines: neutralization of
primary isolates
Recently, a multi-tier approach was recommended for as-
sessing the neutralizing Ab responses generated by candidate
HIV vaccines (Mascola et al., 2005). These recommendations
suggest that initially, immune sera should be tested against “Tier 1
Fig. 1. Humoral immune responses of the groups of immunized rabbits described in Experiment I in Table 1 andMethods. (Left column) Activity of serumAbs binding
in ELISA to MuLV gp70.○, pre-immune sera;•, sera drawn 2 weeks after second protein boost. (Right column) Binding activity of serum drawn 2 weeks after the
second protein boost vs. YU2 gp120 core (□) or YU2 gp120 core containing V3 (▪). y-axis represents OD; x-axis represents the reciprocal of the serum dilutions.
Data shown are from one of two independent experiments.
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in the vaccine and a small number of heterologous viruses that are
known to be highly sensitive to Ab-mediated neutralization”.
Subsequently, testing should be undertaken against “Tier 2 vi-
ruses” (heterologous viruses that match the genetic subtype of the
vaccine) and “Tier 3 viruses” (a multi-clade panel of Tier 2
viruses). Although no Tier 1 panels have been specified, it is
generally acknowledged that Tier 1 viruses are sensitive to Abs
that are specific for V3 and/or CD4i Abs; SF162 and MN are the
only two primary isolates currently acknowledged and cited as
Tier 1 viruses (Law et al., 2007). In the absence of a Tier 1 panel,
we selected primary isolates based on previous studies showing
the ability of anti-V3 mAbs at 25 μg/ml to achieve 50%
neutralization of these viruses (Gorny et al., 2006). The viruses
selected include CA1 (CRF011_cpx, one of the strains used in the
vaccine prime), DJ263 (CRF02_AG), BX08 (clade B), and
NYU129/5 (CRF02_AG). These viruses are more resistant to
anti-V3 mAbs than SF162 (Gorny et al., 2006), and so should
more accurately be identified as “Tier 1+” viruses; for the sake of
brevity, they will be designated here as Tier 1 viruses. In addition,
we tested primary isolates previously shown to be still more
resistant to neutralization (Gorny et al., 2004, 2006) that were
heterologous to the strains on which the immunogens were basedand might therefore be categorized as Tier 2 and 3 viruses,
respectively. These included JR-FL (clade B), 98CN006 (clade
C), 93MW965 (clade C), and 93MW960 (clade C).
The data from two independent experiments assessing the
neutralizing activity against three of four Tier 1 viruses in the
sera of animals receiving the GPGR-based vaccine regimen are
shown in Table 2. The data demonstrate the presence of neu-
tralizing activity in the sera of the animals in the two groups that
received both priming and boosting immunogens; the mean
50% neutralizing titers ranged from 1:13 to ≥1:320 against
three of the four Tier 1 viruses tested, including viruses hetero-
logous to those used to prepare the vaccine constructs. Signi-
ficant neutralization of the CRF02_AG virus NYU129/5 was
not achieved at a serum dilution of 1:20 (data not shown).
Particular attention was placed on the neutralizing activity
against DJ263 in the sera of these rabbits immunized with a
GPGR-based vaccine regimen since DJ263 is a virus with a
clade A Env whose V3 loop carries the GPGQmotif. Results of
one of two experiments are shown in Fig. 2 in which the
neutralizing activity was titrated with sera drawn 2 weeks after
the second protein boost. The sera from Group I-1: −/B dis-
played little or no neutralizing activity; the geometric mean titer
for 50% neutralization (GMT50) in this group, derived from the
Table 2
Neutralizing activity in immune rabbit sera
Group Immunizing
regimen a
DJ263 (CRF02_AG) BX08 (Clade B) CA1 (CRF011_cpx)
GMT50
b % Neutralization due to V3 Abs GMT50
b % Neutralization due to V3 Abs GMT50
b % Neutralization due to V3 Abs
I-1 −/B 1:13 90%c 1:91 79% b1:10 –
I-2 AR/B 1:81 88% 1:132 69% 1:22 68%
I-3 AR/gp120R 1:38 33% ≥1:320 38% 1:47 49%
a Defined in Table 1.
b Geometric mean titers for 50% neutralization derived from all rabbit sera in each group tested in two separate experiments.
c Based on neutralization of DJ263 by sera from this group that contained neutralizing antibodies.
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GMT50 calculated from two experiments for all rabbits in Group
I-2: AR/B was 1:81. Rabbits in Group I-3: AR/gp120R also
mounted a significant neutralizing Ab response, with a GMT50
of 1:38 calculated from the results of two experiments. A dose–
response relationship was demonstrated in the neutralization
assay (Fig. 2), and, it is noteworthy that, when the immunization
regimen focused the immune response on the clade B V3 loop
by using the V3-FPB boost (Group I-2: AR/B), the neutralizing
GMT50 reached levels comparable to those achieved by admin-
istration of the entire gp120 molecule (Group I-2: AR/gp120R)
or that had otherwise required the use of a polyvalent vaccine
cocktail of full-length gp120 molecules delivered as both DNA
and protein (Wang et al., 2006). Moreover, the results reported
here are substantially stronger than those previously achieved
for neutralizing activity in the sera of immunized animals
against heterologous primary isolates using other immunization
approaches (Chakrabarti et al., 2005; Lian et al., 2005).
The efficacy of the boost is shown in Fig. 3: there is minimal
neutralizing activity against DJ263 in sera drawn 2 weeks after
the third DNA prime as opposed to the activity in the sera drawn
2 weeks after the second protein boost. These data confirm
those previously published (Wang et al., 2006) showing that
DNA priming induces relatively low levels of neutralizing Abs,
whereas the protein boost is primarily responsible for the
induction of clearly positive neutralizing Ab responses. For this
reason, all subsequent data are shown for sera drawn 2 weeks
after the second boost.Fig. 2. Titration of neutralizing activity against CRF02_AG virus DJ263 in rabbi
summarized in Experiment I, Table 1, include Group I-1: −/B; Group I-2: AR/B, an
animals in that group, each designated with a different symbol. The percent neutraliza
the pre-bleed serum from the corresponding rabbit. Data shown are from one of twoAs noted above (Table 2; Figs. 2 and 3), there is no significant
quantitative difference in the neutralizing activity against DJ263
in sera from rabbits in Groups I-2: AR/B and I-3: AR/gp120R,
however the ELISA data (Fig. 1) demonstrated a qualitative
difference in the specificity of binding Abs, with the V3B-FP
boosted group (I-2: AR/B) and the gp120 boosted group (I-3: AR/
gp120R) having different profiles of Ab binding reactivities. To
determine if there was also a qualitative difference in the speci-
ficity of the neutralizingAbs in the sera from the different groups,
sera were tested for the neutralization of DJ263 at a 1:20 dilution
with or without pre-incubation with a V3 peptide. Fig. 4 shows a
representative experiment. The data confirm that the sera from
Groups I-2: AR/B and I-3: AR/gp120R are quantitatively similar,
with sera diluted 1:20 giving∼60–90%neutralization. However,
the sera from the rabbits in these groups show a considerable
qualitative difference. Thus, the majority of the neutralizing
activity in sera from Group I-2: AR/B was removed by pre-
incubation with the V3 peptide. In contrast, pre-incubation with
V3 peptide resulted in only a partial reduction in the neutralizing
activity of sera fromGroup I-3: AR/gp120R. The sera from two of
the animals in Group I-1: −/B showed weak neutralizing activity,
and most or all of that activity was due to anti-V3 Abs, as
expected. Pre-incubation of immune sera with 180 μg/ml of a
scrambled peptide with the same amino acid composition as the
V3B consensus 23-mer peptide did not result in any significant
absorption of neutralizing activity (data not shown).
Similar peptide inhibition experiments were performed to
identify the proportion of Abs that neutralize Tier 1 virusest immune sera drawn 2 weeks after the second protein boost. Rabbit groups,
d Group I-3: AR/gp120R. Each panel shows the results with sera from the three
tion was calculated based on the activity of each immune serum vs. the activity in
independent experiments.
Fig. 4. Neutralizing activity against CRF02_AG primary isolate DJ263 in
immune rabbit sera prior to (hatched bars) or after (solid bars) incubation of sera
with 180 μg/ml of a 23-mer peptide representing the V3 consensus sequence
from clade B. Data show the activity in the sera from each of the three rabbits in
Groups I-1: −/B, Group I-2: AR/B, and Group I-3: AR/gp120R, as defined in
Table 1 and are derived from one of two experiments.
Fig. 3. Neutralizing activity in immune rabbit sera (at a final dilution of 1:20)
against CRF02_AG primary isolate DJ263. Data are from the three groups of
rabbits in Experiment I described in Table 1, i.e., Group I-1: −/B; Group I-2: A
R
/B,




. Data from the sera of each of the three rabbits in each
group are displayed as paired bars representing sera drawn 2 weeks after the third
DNA prime (hatched bars), and 2 weeks after the second protein boost (solid bars).
The percent neutralization was calculated based on the activity in the immune sera
vs. the corresponding animal's pre-immune sera. Data shown are from one of two
experiments.
238 S. Zolla-Pazner et al. / Virology 372 (2008) 233–246BX08 and CA1. The results again show that the use of the V3-FP
results in neutralizing Abs that are preferentially V3-specific.
Thus, 69% and 68% of the BX08 and CA1 neutralizing activity,
respectively, in the sera of the Group I-2: AR/B rabbits were
blocked by V3 peptide, where as 38% and 49% of the compara-
ble neutralizing activity was blocked in the sera of the Group I-3:
AR/gp120R rabbits (Table 2). Thus, while boosting with V3-FP
induces a response that is quantitatively similar to that achieved
with whole gp120, using a boosting immunogen with a single
neutralizing epitope is able to focus the immune response such
that neutralizing Abs to that epitope are preferentially produced.
Immune sera from the rabbits receiving the GPGR-based
vaccine regimen were also tested against Tier 2 (JR-FL) and
Tier 3 (98CN006, 93MW965, 93MW960) viruses. 50% neu-
tralization was not detected at final serum dilutions of 1:20.
Immunization with GPGR-based vaccines: neutralization of
pseudoviruses
For many primary isolates, the V3 loop is partially or fully
masked by the V1/V2 loop and/or carbohydrate moieties in Env(Pinter et al., 2004; Wei et al., 2003). As noted above, viruses
with an unmasked V3 loop are generally considered to be Tier 1
viruses, and about 20% of viruses are thought to be Tier 1. One
such virus is the clade B strain SF162 (Krachmarov et al.,
2005). Ninety percent geometric mean titers (GMT90) for the
neutralization of the pseudovirus (psV) carrying the SF162 Env
are 1:41, 1:114, and 1:166 for animals in Group I-1: −/B, Group
I-2: AR/B, and Group I-3: AR/gp120R, respectively (Table 3).
To thoroughly assess the range of V3 diversity that is recog-
nized by anti-V3 Abs in the rabbit immune sera, V3 chimeric
psVs were constructed in which the V3 loop of SF162 was
replaced with the consensus V3 sequences from clades A1, B,
C, F, H, CRF01_AE (E), and CRF02_AG. The GMT90s of the
pre-bleed sera tested against these seven V3 chimeric psVs was
b1:10 (data not shown). In the immune sera of rabbits receiving
the GPGR-based immunizations, the GMT90s were consistently
highest against the psV carrying the clade B V3 consensus
sequence (Table 3), reflecting (a) a preference for the GPGR
motif at the tip of the loop which is homologous to the V3 motif
in both the priming and boosting immunogens used, and (b) the
fact that the V3 sequence of the V3B-FP boosting protein differs
from the consensus B V3 sequence at only a single residue at the
N-terminal base of the loop (Table 1). The GMT90s for Group I-
1: −/B, Group I-2: AR/B, and Group I-3: AR/gp120R against the
psV carrying the consensus V3 sequence of clade B were 1:689,
1:1717, and 1:3308, respectively. Interestingly, the titers against
the chimeric psV carrying the consensus B V3 loop in the
SF162 Env backbone were frequently more than one order of
magnitude higher than the titers against the psV carrying the
wild type Env of SF162 (which differs at three positions from
the V3 consensus B sequence in the central portion of the loop
[Table 3]). While the GMT90s were b1:10 for neutralizing
activity in the sera from animals in each group against psVs
Table 3
90% neutralizing titers for V3 chimeric pseudoviruses
Titers are shown at which RLUs were reduced 90% compared to control wells containing virus alone. Data are geometric mean titers from two to three assays. Dark
gray boxes show titers N1:100; light gray, 1:20–1:99, white, 90% neutralization not achieved at the lowest concentration tested. Columns show neutralizing titers
against pseudoviruses carrying the wild type SF162 Env (SF162wt) and against V3 chimeric SF162 pseudoviruses carrying the consensus sequences of clades B, F, E,
A1 and AG. Consensus V3 sequences inserted into the SF162 backbone Env of psVs are:
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shown), 90% neutralizing titers against psVs carrying the con-
sensusV3 loops of cladesA1,AG, F, and Ewere detected at levels
of 1:20 to 1:274 in the sera of animals that had been primed and
boosted with either V3-FP or gp120 (Group I-2: AR/B and Group
I-3: AR /gp120R) (Table 3). The neutralizing activity against these
chimeric psVs showed a hierarchy with B≫FNENA1NAG.
These data demonstrate the induction of neutralizing Abs that can
recognize the V3 loops of diverse clades.
The V3 chimeric psVs with the SF162 Env backbone
represent Tier 1 viruses, and, as noted, the rabbit immune sera
had significant activity against many of these psVs and against
three of four Tier 1 viruses. Although no activity had been
detected against Tier 2 and 3 viruses, to test further for activity
against Tier 2 viruses, the rabbit sera were assayed against the
Tier 2 standard clade B panel of psVs (Li et al., 2005). None of
the rabbit sera achieved 50% neutralization when tested at a
1:10 dilution (data not shown). Thus, neither Tier 2 viruses nor
Tier 2 psVs were neutralized by the immune rabbit sera.Immunization with multivalent vaccines: anti-V3 binding activity
A second set of rabbits was immunized using multivalent
priming and/or boosting (Table 1). The multivalent approach
was based on previous work showing that broader immune
responses could be elicited with immunogens derived from
diverse HIV clades (Chakrabarti et al., 2005; Lian et al., 2005;
Wang et al., 2006). The sera of animals receiving the multi-
valent vaccine regimen, derived from bleeds taken 2 weeks after
the second protein boost, were titrated for their binding activity
against V3A-, V3B- and V3C-FPs. The data in Table 4 de-
monstrate that the strongest response to all three V3-FPs was
mounted by rabbits in Group II-3: CQ/ABC.
Immunization with multivalent vaccines: neutralization of
primary isolates
To determine if multivalent immunogens would help to
broaden the immune response when, simultaneously, the immune
Fig. 5. Geometric mean titers for 50% neutralization (GMT50) vs. three primary
isolates measured in immune rabbit sera from Experiment II obtained 2 weeks
after the second protein boost. Titers are shown at which RLUs were reduced
50% compared to control wells containing virus and pre-immune serum from the
corresponding animal. The rabbit groups are those described in Table 1 for
Experiment II. Data are compiled from two independent experiments with each
virus.
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ments were performed in which animals received either no DNA
priming (Group II-1: −/ABC), a gp120 DNA prime based on the
clade AR env (Group II-2: AR/ABC), a gp120 DNA prime based
on the clade CQ env (Group II-3: CQ/ABC), or a combined clade
AR and CQ gp120 DNA prime (Group II-4: AR+CQ/ABC). All
animals in these groups received boosts of a cocktail of V3A-,
V3B-, and V3C-FPs. Group II-5: AR/B serves as a “benchmark”,
recapitulating Group I-2: AR/B in the previous set of rabbits.
The immune sera from the rabbits in this experiment were
again tested first for their ability to neutralize Tier 1 primary
isolates which, in this case, included CA1 (CRF02_AG) and
92BR025 (clade C), each used as the basis of the gp120 DNA
prime, and BX08 (clade B), DJ263 (CRF02_AG), and
NYU129/5 (CRF02_AG). While no significant neutralizing
activity was detected in the sera of any of the rabbits when
tested at a dilution of 1:20 against NYU129/5 or 92BR025 (data
not shown), the neutralizing activity demonstrated against pri-
mary isolates DJ263 and BX08 and CA1 is shown in Fig. 5. The
rabbits that received the CQ/ABC regimen (Group II-3) dis-
played the strongest response against DJ263 (GMT50 of 1:559),
the virus that carries the GPGQ V3 motif also found in the CQ
gp120 DNA prime and in the V3A- and V3C-FPs used to boost.
In contrast, the sera from Group II-5: AR/B showed the stron-
gest reactivity against primary isolates BX08 and CA1 carrying
the GPGR V3 motif. Thus, sera from Group II-5: AR/B dis-
played a GMT50 vs. clade B virus BX08 of 1:246, and a GMT50
vs. CA1 (the CRF011_AG virus from which the AR boost was
constructed and which contains a GRGR V3 motif) of 1:111
(Fig. 5).
The sera of the animals immunized with the multivalent
vaccine regimen were also tested against Tier 2 viruses includ-
ing JR-FL (clade B), 98CN006 (clade C), 93MW960 (clade C),
and 93MW965. Fifty percent neutralization was not detected
against any of these Tier 2 primary isolates when tested at a final
serum dilution of 1:20.
Immunization with multivalent vaccines: neutralization of
pseudoviruses
Neutralization experiments were next performed using the
panel of psVs made with the SF162 Env or chimeric forms of
this Env carrying the consensus V3 sequences from clades A1,
AG, B, C, F, E, C and H. The neutralization data with psVsTable 4
Reciprocal half-maximal binding titers to V3A- V3A- and V3C-FPs of immune
sera drawn 2 weeks after the second boost
Group a Immunizing regimen V3A V3B V3C
II-1 −/ABC 1765 b 6556 1418
II-2 AR/ABC 1869 16,469 1869
II-3 CQ/ABC 5580 27,332 5268
II-4 AR+CQ/ABC 3243 20,106 3020
II-5 AR/B 1651 27,227 1354
a Groups as defined in Table 1.
b Reciprocals of the geometric means of the half-maximal binding titers from
the sera of each of the three rabbits in each group.(Table 3) support data from assays against the Tier 1 and 2
viruses showing that Group II-3: CQ/ABC mounts the broadest
response (Fig. 5). The response to the psV carrying the clade B
V3 consensus sequence was strong (NT90 N1:100) in all ani-
mals that received a prime and boost, but the response to the
psVs carrying the GPGQ V3 motif in consensus V3 sequences
of clades F, E, A1 and AG were consistently highest when clade
C gp120 DNAwas used to prime and V3A-, V3B- and V3C-FPs
were used to boost (Group II-3: CQ/ABC; Table 3) It is only in
this latter group that rabbit immune sera achieve a GMT90 N
1:100 for the clades B, F, E, A1 and AG V3 chimeric psVs.
GMT90 levels ≥1:10 were not achieved by sera from any of the
rabbit groups against psVs carrying the clade C or H consensus
V3 sequence. However, GMT50 levels of neutralizing Abs
against these latter psVs were achieved by all groups of animals
receiving both DNA prime and protein boosts, with titers
ranging from 1:15 to 1:85. Group II-3: CQ/ABC again achieved
the highest levels of Abs, with GMT50 vs. clade C and H
chimeric psVs of 1:85 and 1:53, respectively (data not shown).
The sera from these animals receiving the multiclade im-
munofocusing regimen were also assayed against the Tier 2
standard clade B panel of psVs (Li et al., 2005). None of the
rabbit sera achieved 50% neutralization at titers of 1:10 (data
not shown).
Discussion
The experiments described here demonstrate the feasibility
of focusing the immune response on a single protein domain
that elicits neutralizing Abs. The results serve as a proof-of-
principle that the immune response can be focused on selected
regions of the HIV envelope, that the majority of neutralizing
Abs elicited can, indeed, be targeted to the selected epitope, and
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the vaccine constructs used in this work were designed to focus
the immune response on only a single HIV Env epitope, the V3
loop, the incorporation of selected additional neutralizing
epitopes into recombinant vaccines may induce neutralizing
Abs that produce additive, or optimally, synergistic effects.
When the immune response of rabbits was focused on the V3
epitope of the HIV gp120 envelope glycoprotein with the
GPGR-based regimen, Abs were elicited that neutralized three
of four Tier 1 primary viruses including a Tier 1 virus that was
heterologous to the parental strains from which the immunogens
were constructed and that carried the GPGRV3 loop (e.g., clade
B strain BX08), and a heterologous Tier 1 virus carrying the
GPGQ V3 loop (e.g., CRF02_AG strain DJ263); none of four
Tier 2 primary isolates were neutralized. The multiclade immu-
nofocusing technique also resulted in the neutralization of three
of four Tier 1 viruses. Moreover, when sera from the rabbits
immunized with the multiclade regimen were tested against
chimeric psVs carrying unmasked consensus V3 loops from
several clades, GMT90 N1:100 were demonstrable against psVs
carrying the consensus V3 sequences from clades A1, B, F, E,
and AG.
The use of DNA priming and protein boosts has proven to be
one of the best regimens for inducing anti-Env Ab responses
(Barnett et al., 1997; Lu, 2006; Richmond et al., 1998), and
polyvalent vaccines based on the DNA prime/protein boost
approach have proven to induce broader immune responses than
similarmonovalent vaccines (Chakrabarti et al., 2005; Lian et al.,
2005; Wang et al., 2005a). We have now modified and extended
previous work using the DNA prime/protein boost approach by
using polyvalent combinations in both the prime and the boost,
and by focusing the Ab response on a single gp120-neutralizing
epitope, the V3 loop. The results demonstrate that a cross-clade-
neutralizing Ab response can be achieved by using this approach
(Table 3 and Fig. 5). As previously reported (Wang et al., 2005a,
2006), low levels of neutralizing Abs were induced by the
priming alone, but peak Ab responses were elicited only after the
protein boosts (Fig. 3).
Since immunization regimens differ and methods for
measuring neutralization vary, it is often difficult to compare
results from various experiments. To facilitate comparison of
our results with previous experiments, we included a group of
rabbits in Experiment I that were primed with gp120 DNA and
boosted with gp120 protein-a control group immunized with a
regimen similar to those used previously (Richmond et al.,
1998; Wang et al., 2005a). This group served as a standard for
qualitative and quantitative comparisons. Based on comparison
of the results from the sera of the control and experimental
groups, it appears that the immunofocusing vaccine regimens
employed here are at least as good as, and often better than,
results obtained with vaccines targeting the many epitopes of
the HIV Env. For example, in rabbits primed with gp120JR-FL or
gp140JR-FL DNA and boosted with EnvJR-FL, neutralizing Abs
were induced to the relatively resistant homologous JR-FL
strain and to SF162, but little or no neutralizing activity was
detected against other clade B primary isolates or against pri-
mary isolates from other clades (Wang et al., 2005a). The resultswith the multiclade immunofocusing protocol presented here
also exceed, in qualitative and quantitative terms, those recently
published by Law et al. (Law et al., 2007). In the latter paper,
rabbits were given four priming doses of codon-optimized JR-
FL gp120 DNA and three boosts with a modified form of JR-FL
gp120 in which the V1V2 loop was replaced with the gp41
MPER region containing two deleted residues immediately
preceding the 4E10 epitope. Sera from these immunized rabbits
displayed ND50s vs. a psV carrying the Env of SF162 of 1:10–
1:320, however 90% neutralization was never achieved. In
contrast, the sera from animals primed and boosted in the
experiments described above displayed ND50s against the
SF162 psV that ranged from 1:190 to 1:3550 (data not shown),
and ND90s in all primed and boosted rabbits in the range of 1:14
to 1:190 (Table 3). The results presented above for the multi-
clade immunofocusing regimen also compare favorably, in
terms of the titer and breadth of the response, with the results of
previously published multiclade immunizations using immuno-
gens that included all or most of the Env epitopes (Chakrabarti
et al., 2005; Lian et al., 2005; Wang et al., 2006). The current
study represents a step forward by showing that, in focusing the
immune response on a single neutralizing epitope, a functional
Ab response is achieved that is better than or comparable to that
induced by Env immunogens possessing a multitude of B cell
epitopes. The results suggest that focusing the immune response
on a few, carefully selected neutralizing epitopes and optimizing
the structure of these epitopes and the scaffolds on which they
are presented could result in a stronger and broader neutralizing
Ab response than that induced by Env proteins carrying the
many epitopes of the Env.
Interestingly, the GPGR-based and multiclade immunization
regimens used to prime and boost the rabbits in the two expe-
riments described here resulted in approximately comparable
neutralizing Ab responses against the Tier 1 clade B primary
isolate BX08 and against the psV carrying the clade B V3
consensus sequence (Tables 2 and 3; Fig. 5). In contrast, im-
munizationwith clade C gp120DNA and the polyvalent cocktail
of V3-FPs (Group II-3: CQ /ABC) elicited the broadest and/or
strongest response against the Tier 1 primary isolate DJ263
(CRF02_AG) which carries the GPGQ V3 motif (Fig. 5) and
against the chimeric psVs carrying V3 loops with the GPGQ
motif (Table 3). These data support prior data that suggest an
antigenic difference between viruses carrying the GPGR and
GPGQ V3 motifs (Zolla-Pazner et al., 2004) and document that
anti-V3 Ab responses induced by “GPGR viruses” favor neu-
tralization of GPGR viruses but that anti-V3 Ab responses
induced by non-B “GPGQ viruses” neutralize both GPGQ and
GPGR viruses (Gorny et al., 2006; Krachmarov et al., 2005).
Group II-3: CQ /ABC is further distinguished as the only
immunized group primed with the full dose of a gp120 DNA
construct carrying the GPGQ V3 motif. Interestingly, neither
rabbits in Group II-2: AR/ABC or Group II-4: AR+CQ/ABC
produced Abs of comparable breadth or potency. A possible
explanation for this is that these two latter groups were primed,
respectively, with AR, a construct carrying the GPGRV3 motif
or with AR+CQ, a priming dose containing half the dose of each
prime relative to the dose of CQ , the clade C (GPGQ) priming
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of these groups suggest that when a combination of GPGR and
GPGQ immunogens are used for priming, the GPGR immuno-
gen is dominant over the GPGQ immunogen in eliciting the Ab
responses. Other explanations for these findings include the
possibility that a clade C gp120 DNA prime is superior to a
clade A gp120 DNA prime, and/or that the differences noted are
due to other factors contributed by the individual gp120 con-
structs used in these experiments.
The results of the experiments reported here demonstrate that
it is possible to focus the immune response on an epitope that
elicits neutralizing Abs, in this case, the V3 loop. Thus, the
majority of neutralizing Abs elicited with a gp120 DNA prime
and V3-FP boost were directed to V3; in contrast, only the
minority of neutralizing Abs elicited with a DNA prime and
gp120 protein boost were directed against V3 (Fig. 4 and
Table 2). It is also noteworthy that when a neutralizing Ab
response was elicited with the V3-FP boost, the cross-clade-
neutralizing activity could be significantly blocked by a single
V3 peptide derived from the clade B consensus sequence. This
stands in contrast to the work of Chakrabarti et al. (2005) in
which immunization of guinea pigs was carried out with DNA
encoding gp145ΔCFI of one or several clades and replication-
defective recombinant adenoviruses encoding the gp140ΔCFI of
the same strains. In these latter experiments, when the polyvalent
regimen was used, cross-clade neutralizing Abs were elicited,
but neutralizing titers did not exceed 1:5 and serum absorption
with V3 peptides did not remove the neutralizing activity.
In summary, the use of vaccine constructs that are capable of
immunofocusing the humoral immune response provides a
platform for improving further both the strength and breadth of
the Ab response. This may be accomplished by (a) defining the
best combinations of parental strains from which to build the
priming and boosting immunogens, (b) designing immunogens
that will optimally present the neutralizing epitopes and produce
Abs of higher titer and affinity, and (c) ultimately focusing the
immune response on additional epitopes which have been shown
to induce protective Abs.
Methods
Construction of codon-optimized HIV env DNA vaccine
constructs
The codon usage of env genes from HIV CRF011_cpx
primary isolate CA1 and clade C primary isolate 92BR025 (C1)
were analyzed with the MacVector software 6.3 against codon
preference in Homo sapiens. The codons in CA1 and C1 env
genes that are less preferred in mammalian cells were changed to
the preferred codons in mammalian systems to promote higher
expression of the Env proteins. The codon optimization strategy
was not limited to changes of codons for mammalian usage.
Sequence optimization was also performed to make the mRNA
more stable and the genes more favorable for transcriptional and
translational processes. During the sequence optimization, the
following cis-acting sequence motifs were avoided: internal
TATA-boxes, chi-sites and ribosomal entry sites, AT-rich or GC-rich sequence stretches, ARE, INS, CRS sequence elements,
cryptic splice donor and acceptor sites, and branch points. De-
spite such DNA level sequence changes, the final codon-opti-
mized CA1 and C1 env DNA sequences still produce the same
Env amino acid sequences that occur in the parental HIV-1
primary isolates. These codon-optimized env genes were chemi-
cally synthesized by Geneart (Regensburg, Germany).
To make codon-optimized CA1 and C1 gp120 DNA vac-
cines, the codon-optimized gp120 gene inserts were first PCR-
amplified from the codon-optimized CA1 or C1 env genes. A
pair of primers, gp120.CA1-opt1 (5′ GTCGCTCGCTAGC-
CTGTGGGTGACCGTG 3′) and gp120.CA1-opt2 (5′ ACC-
TACGGATCCTTACTGCACCACTCTTCTCTTGGC 3′),
were used to amplify the codon-optimized gp120 CA1 gene
insert. The priming constructs, tp120.Syn-7 (5′ GTCGCTC-
CAGCTAGCCTGTGGGTGACCGTGTACTACGGC 3′) and
gp120.Syn-10 (5′ CGACGGATCCTTACTCCACCACGCGG-
CGCTTGGC 3′), were used to amplify the codon-optimized
gp120 C1 gene insert. Then, the optimized CA1 or C1 gp120
gene inserts were cloned into the DNAvaccine vector pJW4303
(Wang et al., 2005b) at the NheI and BamHI sites downstream
of a human tissue plasminogen activator (tPA) leader sequence,
substituting the natural HA leader sequence. The DNA vaccine
plasmids were prepared from Escherichia coli (HB101 strain)
with a Mega purification kit (Qiagen, Valencia, CA) for in vivo
animal immunization studies.
Protein immunogens
The V3-FPs contain a 45-amino-acid domain encompassing
the V3 sequences of either JR-CSF (clade B), 92UG037.08
(clade A) or 93IN904 (clade C) (see Table 1). The V3 regions
are joined to the C-terminus of a 263 amino acid fragment of the
Friend murine leukemia virus (MuLV) gp70, as previously
described (Kayman et al., 1994). To facilitate purification, the
His-8 and Gln-9 of this gp70 protein were replaced with a
sequence of six His residues. The V3 fragments in the fusion
proteins contain the disulfide-bonded loop and three sites for
N-linked glycosylation, one within the V3 loop and one on each
flank. The clade B V3-fusion protein (V3B-FP) was expressed
in Chinese hamster ovary (CHO) cells from a glutamine syn-
thetase vector, pEE14 (CellTech, Cambridge, UK) containing
the human cytomegalovirus major immediate-early promoter
(Kayman et al., 1994). Similarly, clade A and clade C V3-fusion
proteins (V3A- and V3C-FPs) were cloned into pcDNA3.1zeo
(−) (Invitrogen, Carlsbad, CA) and expressed in CHO cells
(Krachmarov et al., 2005). All fusion proteins were purified on
Ni2+-nitrilotriacetic acid resin (NTA Superflow; Qiagen, Valen-
cia, CA) as described (Krachmarov et al., 2001).
Immunization protocol
Female New Zealand White (NZW) rabbits 6–8 weeks old
(with a body weight of ∼2 kg) were purchased from Millbrook
Farm (Amherst, MA) and housed in the animal facility managed
by the Department of Animal Medicine at the University of
Massachusetts Medical School in accordance with an IACUC-
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immunizations at weeks 0, 2, and 4 using a Bio-Rad Helios gene
gun (Bio-Rad Laboratories, Hercules, CA). The gp120 DNA
vaccine plasmids or the negative control pJW4303 vector
plasmid was coated onto 1.0-μm gold beads at a ratio of 2 μg of
DNA per mg of gold. Each gene gun shot delivered 1 μg of
DNA to a total of 36 non-overlapping sites on the shaved
abdominal skin of each rabbit at each of the three priming
immunizations. The animals then received two boosts with
recombinant gp120 JR-FL protein (provided by Dr. O. Sharma
through the NIH AIDS Research and Reference Reagent Pro-
gram, catalog no. 4598) or with one or more of the V3-FPs at
weeks 10 and 14 (Table 1). A total of 100 μg per injection of
recombinant gp120 protein or of V3-FP(s) was administered
intramuscularly with IFA. Blood was collected prior to immu-
nization and 2 weeks after each immunization.
Measurement of Ab levels by ELISA
To determine serum Ab reactivity, affinity-purified mamma-
lian-expressed YU2 gp120 core and YU2 gp120 core+V3 was
used, as provided by Drs. M. Tang and R. Wyatt (Wu et al.,
1996a). The YU2 V3 sequence is CTRPNNNTRKSINIGP-
GRALYTTGEIIGDIRQAHC. The V3A-, V3B-, and V3C-FPs
described above were also used. The carrier protein gp70 was
also used as a control antigen in ELISA experiments; it was
expressed in CHO cells and purified from culture supernatants
as previously described (Krachmarov et al., 2001). The proteins
were coated onto wells of microplates (Immunolon 4, Dynatech,
Chantilly, VA) overnight at 4 °C at concentrations of 1 μg/ml,
with the exception of the V3-FPs which were coated at 0.4–
0.5 μg/ml. Plates were washed with PBS/0.2% Tween-20
(PBST), serum samples were added with blocking buffer (5%
FCS, 5% sheep serum, and 2.5% BSA in PBS) and incubated
for 1 h at 37 °C. After rinsing with PBST, anti-rabbit–IgG–HRP
(Bio-Rad Laboratories, Hercules, CA) was added for 30 min at
37 °C. The wells were washed with PBS, color developed with
100 μl TMB peroxidase substrate (KPL Labs, Gaithersburg,
MD), the reaction was stopped with 1 M HCl, and absorbance
was measured at 450 nm.
Neutralization assays
Neutralization of primary isolates
JC53-BL cells (also termed TZM-bl cells) were obtained from
theNIHAIDSResearch andReferenceReagent Program (catalog
no. 8129). This is a genetically engineered HeLa cell clone that
expresses CD4 and CCR5 and contains Tat-responsive reporter
genes for firefly luciferase and E. coli β-galactosidase under the
regulatory control of the HIV long terminal repeat. Cell lines were
maintained in growthmedium, consisting ofDulbecco'smodified
Eagle's medium (Gibco BRL Life Technologies, Carlsbad, CA),
10% heat-inactivated fetal bovine serum, 50 U/ml penicillin,
50 μg/ml streptomycin and 2 mM L-glutamine (BioWhittaker,
Walkersville, MD).
Neutralizing activity against primary isolates was measured
as the reduction in luc reporter gene expression after a singleround of virus infection in JC53-BL cells as described pre-
viously (Li et al., 2005). Briefly, 200 TCID50 of virus was
incubated with various dilutions of test serum samples for 1 h
at 37 °C in a total volume of 150 μl growth medium in 96-well
flat-bottom culture plates (Corning-Costar, Acton, MA). For
peptide inhibition studies, a 23-mer V3 peptide representing the
V3 clade B consensus sequence (TRPNNNTRKSIHIGPGRA-
FYTTG) was incubated for 30 min at a final concentration of
180 μg/ml with rabbit serum, and then 200 TCID50 of virus in
culture medium was added and incubated for a further 1 h at
37 °C (Bio-Synthesis, Inc., Lewisville, TX). Freshly trypsi-
nized cells (1×104 cells) were added to each well and main-
tained in culture medium containing 1 μM indinavir sulfate
(NIH AIDS RRRP, catalog no. 8145). When necessary for
efficient infection, DEAE-dextran was added at a final con-
centration of 25 μg/ml. The background controls contained
cells only, while the virus controls contained cells plus virus.
After a 48 h incubation, 200 μl of growth medium was
removed from each well and 50 μl of Bright Glo reagent
(Promega, Madison, WI) was added. This was followed by a
two min incubation at room temperature to allow cell lysis,
transfer to 96-well black solid plates (Corning Costar, Acton,
MA), and measurement of luminescence using a Lumimark
Plus microplate reader (Bio-Rad Laboratories, Hercules, CA).
The percent neutralization for immune rabbit sera was cal-
culated relative to the effect of preimmune serum from the
same rabbit. Thus, for all dilutions of sera, the percent neu-
tralization was calculated based on the RLU in the presence of
immune sera from a given animal divided by the RLU in the
presence of the same dilution of preimmune serum from the
same animal. The 50% neutralizing titer was determined from
the linear portion of the titration curve using the method of
Least Squares.
Neutralization of pseudoviruses
The env expression vectors for chimeric forms of SF162 env
with various consensus V3 sequences were generated by intro-
ducing the modifications sequentially by QuikChange site-
directed mutagenesis (Stratagene, La Jolla, CA), as described
(Krachmarov et al., 2006). Plasmids expressing the reference
panel of 12 subtype B HIV-1 Env clones described by (Li et al.,
2005) were obtained from the NIH AIDS RRRP (Catalog
#11227). The infectious pseudotyped viruses were generated by
co-transfection of 293 cells with an env expression vector and
with the complementing vector pNL4-3.Luc.R-E− (NIH AIDS
RRRP, catalog no. 3418, donated by Dr. Nathaniel Landau)
(Connor et al., 1995; He et al., 1995). Transfections were per-
formed in tissue culture dishes using TransIT-LT1 Reagent
(Mirus Bio Corporation, Madison, WI) according to the manu-
facturer's protocol.
Neutralizing activity was determined as previously described
(Krachmarov et al., 2001) with a single-cycle infectivity assay
using virions generated from the env-defective luciferase-ex-
pressing pNL4-3.Luc.R-E− (Connor et al., 1995) pseudotyped
with a molecularly cloned HIV env of interest. In brief, psVs
were incubated with serial dilutions of sera from immunized
rabbits for 1.5 h at 37 °C, and then added to U87-T4-CCR5
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(10 μg/ml). After 24 h, cells were re-fed with RPMI medium
containing 10% FBS and 10 μg/ml polybrene, followed by an
additional 24–48 h incubation. Luciferase activity was deter-
mined 48–72 h post-infection with a microtiter plate lumin-
ometer (HARTA, Inc., Gaithersburg, MD) using assay reagents
from Promega, Inc. (Madison, WI). Geometric mean titers for
90% neutralization (GMT90) were determined by interpolation
from neutralization curves and are averages of at least two
independent assays.
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